BioSpace News Archive

Hepion Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis, announced the postponement of its adjourned 2021 Annual Meeting of Stockholders that was to be held on July 23, 2021, at 9:00 a.m. Eastern Time due to a lack of a quorum.

Sensient Technologies Corporation (NYSE: SXT) reported consolidated revenue of $335.8 million in this year’s second quarter compared to $323.1 million in last year’s second quarter.

HTG Molecular Diagnostics , Inc. today announced that, on July 13th and July 22nd, 2021 the Compensation Committee of the HTG Board of Directors granted inducement stock option awards to purchase an aggregate of 30,000 shares of common stock to two employees who have recently joined HTG.

Ocular Therapeutix, Inc. announced multiple scientific presentations at the 2021 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting being held July 23-27, 2021 in Las Vegas, NV.

New clinical trial by Taiwan’s GNT Biotech & Medicals Corporation (GNTbm) combines therapeutic options for more effective treatment of breast cancer

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending marketing authorization for Moderna’s COVID-19 vaccine (Spikevax) to include adolescents 12 years of age and older.

The report highlights the trends prevailing in the global allergy treatment market, along with market drivers and deterrents.

The home sequential compression devices market was valued at US$ 992.49 million in 2021 and is projected to reach US$ 1,572.81 million by 2028; it is expected to grow at a CAGR of 6.8% from 2021 to 2028.

The Tel-Intensive Care Unit market was valued at US$ 1,031.2 million in 2017 and it is projected to reach US$ 4,884.80 million by 2025; it is expected to grow at a CAGR of 22.5% from 2018 to 2025.

New efficacy and biomarker data to be featured in panel presentation on Wednesday, July 28.